<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591627</url>
  </required_header>
  <id_info>
    <org_study_id>1st Department of Cardiology</org_study_id>
    <nct_id>NCT03591627</nct_id>
  </id_info>
  <brief_title>Left Atrial Thrombus on Transesophageal Echocardiography</brief_title>
  <acronym>LATTEE</acronym>
  <official_title>Left Atrial Thrombus on Transesophageal Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the prevalence of left atrial thrombus in patients with
      atrial fibrillation (AF) or atrial flutter (AFI), in whom transesophageal echocardiography is
      performed before AF/AFl cardioversion or ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) and atrial flutter (AFI) increase the risk of thromboembolic events
      by promoting clot formation in the left atrium (LA). Transesophageal echocardiography (TEE)
      is routinely used to exclude the presence of an LA thrombus before AF/AFI ablation or
      cardioversion. So far, it has not been established what is the optimal combination of
      noninvasive parameters for thromboembolic risk stratification in this setting. The present
      study is aimed to compare the prevalence of LA thrombus in patients on different
      anticoagulant regimens, identify predictors of LA thrombus and validate the newly developed
      CHA2DS2-VASc-AF-GFR score (and to compare its predictive value in LA thrombus identification
      with those of the CHA2DS2-VASc and the CHADS2 scores).

      The study protocol all patients with AF or AFl in whom TEE will be performed (to assess their
      eligibility for cardioversion or ablation), hospitalized in a participating center during
      study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Assessment of the prevalence of LA thrombus in patients with AF/AFI, in whom TEE is performed before AF/AFl cardioversion or ablation.</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the prevalence of LA thrombus in patients on different anticoagulant regimens.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the predictors of LA thrombus.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of the the newly developed CHA2DS2-VASc-AF-GFR score (and to compare its predictive value in LA thrombus identification with those of the CHA2DS2-VASc and the CHADS2 scores).</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Transesophageal Echocardiography</condition>
  <condition>Ablation</condition>
  <condition>Cardioversion</condition>
  <condition>Thrombus; Embolism</condition>
  <arm_group>
    <arm_group_label>AF or AFl patients</arm_group_label>
    <description>Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transesophageal echocardiography</intervention_name>
    <description>Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.</description>
    <arm_group_label>AF or AFl patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for
        cardioversion or ablation), hospitalized in a participating center during study period.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with AF or AFl in whom TEE will be performed (to assess their eligibility
             for cardioversion or ablation), hospitalized in a participating center during study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>1st Department of Cariology of Medcial University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Kapłon-Cieślicka, PhD</last_name>
      <phone>+48 22 599 19 58</phone>
      <email>agnieszka.kaplon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Agnieszka Kapłon-Cieślicka, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Gawałko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Budnik, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iwona Gorczyca, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 7, 2018</study_first_submitted>
  <study_first_submitted_qc>July 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>November 2, 2018</last_update_submitted>
  <last_update_submitted_qc>November 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Agnieszka Kaplon-Cieslicka</investigator_full_name>
    <investigator_title>Agnieszka Kapłoń-Cieślicka, Medical University of Warsaw</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Atrial Flutter</keyword>
  <keyword>Transesophageal echocardiography</keyword>
  <keyword>Ablation</keyword>
  <keyword>Cardioversion</keyword>
  <keyword>Thrombus; Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

